Elevated levels of circulating tumor necrosis factor-alpha, interferon-gamma, and interleukin-2 in systemic reactions induced by anti-CD4 therapy in patients with rheumatoid arthritis.
Horneff
G
G
Krause
A
A
Emmrich
F
F
Kalden
J R
JR
Burmester
G R
GR
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000097:blood / Q000276:immunology / Q000628:therapy*; D015415:Biomarkers / Q000097:blood; D015704:CD4 Antigens / Q000276:immunology*; D006801:Humans; D007074:Immunoglobulin G / Q000276:immunology; D007165:Immunosuppression Therapy / Q000009:adverse effects; D007371:Interferon-gamma / Q000097:blood*; D007375:Interleukin-1 / Q000494:pharmacology; D007376:Interleukin-2 / Q000097:blood*; D016853:Muromonab-CD3; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis*
D000911:Antibodies, Monoclonal; D015415:Biomarkers; D015704:CD4 Antigens; D007074:Immunoglobulin G; D007375:Interleukin-1; D007376:Interleukin-2; D016853:Muromonab-CD3; D014409:Tumor Necrosis Factor-alpha; D007371:Interferon-gamma